Author

R. Heukers

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

M. J. Smit· 2 shared A. Amcheslavsky· 1 shared A. C. Kruse· 1 shared A. Wallace· 1 shared B. Kellam· 1 shared B. Pierce· 1 shared B. W. Bardoel· 1 shared C. McMahon· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

M. J. Smit

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies

E. M. Struijf, K. I. De la O Becerra, M. Ruyken, F. van Oosterom, D. Y. Siere, D. A. C. Heesterbeek, E. Dolk, R. Heukers, B. W. Bardoel, P. Gros, S. H. M. Rooijakkers

This study identifies and characterizes two high-affinity anti-C5 nanobodies that inhibit C5 cleavage and recognize distinct epitopes, including a variant not targeted by Eculizumab.

bioRxiv · Feb 22, 2023Immunology

Targeting the latent human cytomegalovirus reservoir with virus specific nanobodies

T. W. M. De Groof, E. G. Elder, R. Heukers, E. Y. Lim, M. Wills, J. H. Sinclair, M. J. Smit

This study develops a nanobody that partially inhibits HCMV receptor signaling and enhances T-cell killing of latently infected monocytes, offering a potential therapy for clearing HCMV reservoirs in transplant patients.

Nature Communications · Jul 21, 2021Peer-reviewedMicrobiology

Oral administration of a single anti-CfaE nanobody provides broadly cross-protective immunity against major pathogenic Enterotoxigenic Escherichia coli strains

A. Amcheslavsky, A. Wallace, M. Ejemel, Q. Li, C. McMahon, M. Stoppato, S. Giuntini, Z. A. Schiller, J. Pondish, J. R. Toomey, R. Schneider, J. Meisinger, R. Heukers, A. C. Kruse, E. M. Barry, , Y. Wang

This study shows that oral administration of a single nanobody provides broad protection against multiple ETEC strains by targeting conserved epitopes.

bioRxiv · Jun 16, 2020 · PreprintMicrobiology

Monitoring ligand-induced changes in receptor conformation with NanoBiT conjugated nanobodies

M. Soave, R. Heukers, B. Kellam, J. Woolard, M. J. Smit, S. J. Briddon, S. Hill

The paper uses nanobodies conjugated with NanoBiT to monitor ligand-induced conformational changes in the CXCR4 receptor.

bioRxiv · Apr 21, 2020 · PreprintPharmacology & Toxicology